Research
Hormonal
The STEP HFpEF and SELECT trials demonstrated that semaglutide improves clinical outcomes in obese HFpEF patients and reduces cardiovascular and heart failure events in non-diabetic obese patients.
Practitioners should consider semaglutide as a treatment option for improving outcomes in obese HFpEF patients.
StrongSupportsmedium confidence
The STEP HFpEF (Semaglutide Treatment Effect in People with obesity and HFpEF) and SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trials recently demonstrated that the glucagon-like peptide 1 analogue, semaglutide, improves various aspects of clinical outcomes in obese HFpEF patients and significantly reduces cardiovascular and heart failure events in non-diabetic obese patients.
Why this rating
Based on the mention of large trials (STEP HFpEF and SELECT).
Source
Targeting obesity for therapeutic intervention in heart failure patients
Ryosuke Sato et al. · Expert Review of Cardiovascular Therapy · 2024
DOI 10.1080/14779072.2024.2363395
reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →